1507 related articles for article (PubMed ID: 19249153)
1. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
2. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group.
Calais da Silva F; Calais da Silva FM; Gonçalves F; Santos A; Kliment J; Whelan P; Oliver T; Antoniou N; Pastidis S; Marques Queimadelos A; Robertson C
Eur Urol; 2014 Aug; 66(2):232-9. PubMed ID: 23582949
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
4. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
[TBL] [Abstract][Full Text] [Related]
5. Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.
Kaneko Y; Maekawa S; Arakaki R; Okada Y; Terada N; Nishimura K
Hinyokika Kiyo; 2006 Apr; 52(4):259-64. PubMed ID: 16686352
[TBL] [Abstract][Full Text] [Related]
6. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.
Mottet N; Van Damme J; Loulidi S; Russel C; Leitenberger A; Wolff JM;
BJU Int; 2012 Nov; 110(9):1262-9. PubMed ID: 22502816
[TBL] [Abstract][Full Text] [Related]
7. Intermittent complete androgen blockade in metastatic prostate cancer.
Rambeaud JJ
Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
[TBL] [Abstract][Full Text] [Related]
8. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.
Youssef E; Tekyi-Mensah S; Hart K; Bolton S; Forman J
Am J Clin Oncol; 2003 Oct; 26(5):e119-23. PubMed ID: 14528085
[TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
Pummer K; Lehnert M; Stettner H; Hubmer G
Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
[TBL] [Abstract][Full Text] [Related]
10. Mature results of the Ottawa phase II study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcome.
Malone S; Perry G; Eapen L; Segal R; Gallant V; Dahrouge S; Crook J; Spaans JN
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):699-706. PubMed ID: 17379438
[TBL] [Abstract][Full Text] [Related]
11. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
12. Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).
Schulman C; Cornel E; Matveev V; Tammela TL; Schraml J; Bensadoun H; Warnack W; Persad R; Salagierski M; Gómez Veiga F; Baskin-Bey E; López B; Tombal B
Eur Urol; 2016 Apr; 69(4):720-727. PubMed ID: 26520703
[TBL] [Abstract][Full Text] [Related]
13. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
14. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer.
Salonen AJ; Taari K; Ala-Opas M; Viitanen J; Lundstedt S; Tammela TL;
J Urol; 2012 Jun; 187(6):2074-81. PubMed ID: 22498230
[TBL] [Abstract][Full Text] [Related]
15. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
16. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
17. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
Bañez LL; Blake GW; McLeod DG; Crawford ED; Moul JW
BJU Int; 2009 Aug; 104(3):310-4. PubMed ID: 19239458
[TBL] [Abstract][Full Text] [Related]
18. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
19. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]